- Report
- July 2024
- 140 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- March 2025
- 182 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- January 2025
- 138 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- August 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- January 2022
- 115 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- January 2024
- 103 Pages
Global
€4749EUR$4,995USD£3,989GBP
- Report
- May 2022
- 69 Pages
Middle East, Africa
From €1426EUR$1,500USD£1,198GBP
- Report
- April 2022
- 200 Pages
Global
From €3389EUR$3,565USD£2,847GBP
The Rapid Plasma Reagin (RPR) Test is a point-of-care diagnostic test used to detect syphilis. It is a non-treponemal test, meaning it does not detect the presence of the bacteria that causes syphilis. The test is performed by taking a sample of blood and then testing it for the presence of antibodies to the bacteria. The results of the test are usually available within minutes. The RPR Test is used in a variety of settings, including hospitals, clinics, and laboratories. It is also used in public health programs to screen for syphilis in high-risk populations.
The RPR Test market is a growing segment of the point-of-care diagnostics industry. It is used in a variety of settings, including hospitals, clinics, and laboratories. Companies in the market include Abbott, Siemens, Roche, and Alere. Show Less Read more
